FIGURE 6.

Mean predicted percentage inhibition of MCP‐1 in part A^a of the study (safety population^b). The mean predicted percentage inhibition of MCP‐1 at 1 hour post‐dose (left) and 4‐hours post dose (right) in participants in part A treated with single doses of GSK3358699 of 1, 3, 10, 20, 30 and 40 mg. ^aPart A was a single ascending‐dose crossover study in two interlocking cohorts. Each participant received a maximum of two single ascending oral doses of GSK3358699 (1, 3, 10, 20, 40 or 30 mg) and one dose of placebo. ^bThe safety population consisted of all randomized participants who received at least one dose of study treatment